Drug approval process for acute heart failure syndrome in the United States

Ileana L. Pina, Shari L. Targum

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The history of drug approval that targets the heart failure (HF) population has been subject to the advancements that have been made in the field of HF. A better understanding of the pathophysiology of the HF syndrome, with its complexity and an ever-growing number of patients, has led to an evolution in thinking at the Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products. Once thought of as a terminal disorder without much hope even of palliation, heart failure therapies have emerged as powerful agents that can impact mortality and morbidity and may alter the course of the disease. The therapeutic choices through the years have targeted the concepts that were in vogue in each era. As an example, when inotropic derangement was thought to be the primary cause of HF, several inotropic therapies emerged and were approved based on a small amount of data.1 As the neurohormonal hypothesis was tested, drugs were targeted to this important axis, and the mortality and morbidity improved.

Original languageEnglish (US)
Title of host publicationAcute Heart Failure
PublisherSpringer London
Pages899-908
Number of pages10
ISBN (Print)9781846287817
DOIs
StatePublished - 2008
Externally publishedYes

Fingerprint

Drug Approval
Heart Failure
Morbidity
Mortality
United States Food and Drug Administration
Therapeutics
History
Kidney
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Drug approval process for acute heart failure syndrome in the United States. / Pina, Ileana L.; Targum, Shari L.

Acute Heart Failure. Springer London, 2008. p. 899-908.

Research output: Chapter in Book/Report/Conference proceedingChapter

Pina, Ileana L. ; Targum, Shari L. / Drug approval process for acute heart failure syndrome in the United States. Acute Heart Failure. Springer London, 2008. pp. 899-908
@inbook{fd771fdc76e4485bb531bf156843ad89,
title = "Drug approval process for acute heart failure syndrome in the United States",
abstract = "The history of drug approval that targets the heart failure (HF) population has been subject to the advancements that have been made in the field of HF. A better understanding of the pathophysiology of the HF syndrome, with its complexity and an ever-growing number of patients, has led to an evolution in thinking at the Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products. Once thought of as a terminal disorder without much hope even of palliation, heart failure therapies have emerged as powerful agents that can impact mortality and morbidity and may alter the course of the disease. The therapeutic choices through the years have targeted the concepts that were in vogue in each era. As an example, when inotropic derangement was thought to be the primary cause of HF, several inotropic therapies emerged and were approved based on a small amount of data.1 As the neurohormonal hypothesis was tested, drugs were targeted to this important axis, and the mortality and morbidity improved.",
author = "Pina, {Ileana L.} and Targum, {Shari L.}",
year = "2008",
doi = "10.1007/978-1-84628-782-4_84",
language = "English (US)",
isbn = "9781846287817",
pages = "899--908",
booktitle = "Acute Heart Failure",
publisher = "Springer London",

}

TY - CHAP

T1 - Drug approval process for acute heart failure syndrome in the United States

AU - Pina, Ileana L.

AU - Targum, Shari L.

PY - 2008

Y1 - 2008

N2 - The history of drug approval that targets the heart failure (HF) population has been subject to the advancements that have been made in the field of HF. A better understanding of the pathophysiology of the HF syndrome, with its complexity and an ever-growing number of patients, has led to an evolution in thinking at the Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products. Once thought of as a terminal disorder without much hope even of palliation, heart failure therapies have emerged as powerful agents that can impact mortality and morbidity and may alter the course of the disease. The therapeutic choices through the years have targeted the concepts that were in vogue in each era. As an example, when inotropic derangement was thought to be the primary cause of HF, several inotropic therapies emerged and were approved based on a small amount of data.1 As the neurohormonal hypothesis was tested, drugs were targeted to this important axis, and the mortality and morbidity improved.

AB - The history of drug approval that targets the heart failure (HF) population has been subject to the advancements that have been made in the field of HF. A better understanding of the pathophysiology of the HF syndrome, with its complexity and an ever-growing number of patients, has led to an evolution in thinking at the Food and Drug Administration (FDA) Division of Cardiovascular and Renal Products. Once thought of as a terminal disorder without much hope even of palliation, heart failure therapies have emerged as powerful agents that can impact mortality and morbidity and may alter the course of the disease. The therapeutic choices through the years have targeted the concepts that were in vogue in each era. As an example, when inotropic derangement was thought to be the primary cause of HF, several inotropic therapies emerged and were approved based on a small amount of data.1 As the neurohormonal hypothesis was tested, drugs were targeted to this important axis, and the mortality and morbidity improved.

UR - http://www.scopus.com/inward/record.url?scp=84887915514&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887915514&partnerID=8YFLogxK

U2 - 10.1007/978-1-84628-782-4_84

DO - 10.1007/978-1-84628-782-4_84

M3 - Chapter

SN - 9781846287817

SP - 899

EP - 908

BT - Acute Heart Failure

PB - Springer London

ER -